NYSE:ZTS

Zoetis Competitors

$185.53
+0.95 (+0.51 %)
(As of 06/15/2021 03:16 PM ET)
Add
Compare
Today's Range
$183.15
$185.75
50-Day Range
$155.90
$184.58
52-Week Range
$130.40
$184.77
Volume29,534 shs
Average Volume1.95 million shs
Market Capitalization$88.08 billion
P/E Ratio50.01
Dividend Yield0.55%
Beta0.65

Zoetis (NYSE:ZTS) Vs. JNJ, PFE, LLY, ABBV, MRK, and BMY

Should you be buying ZTS stock or one of its competitors? Companies in the sub-industry of "pharmaceuticals" are considered alternatives and competitors to Zoetis, including Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly and (LLY), AbbVie (ABBV), Merck & Co., Inc. (MRK), and Bristol-Myers Squibb (BMY).

Zoetis (NYSE:ZTS) and Johnson & Johnson (NYSE:JNJ) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Zoetis and Johnson & Johnson's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.30%55.11%14.70%
Johnson & Johnson17.95%34.62%13.13%

Risk & Volatility

Zoetis has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500. Comparatively, Johnson & Johnson has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Johnson & Johnson pays an annual dividend of $4.24 per share and has a dividend yield of 2.6%. Zoetis pays out 26.0% of its earnings in the form of a dividend. Johnson & Johnson pays out 52.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and Johnson & Johnson has raised its dividend for 59 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Insider & Institutional Ownership

90.2% of Zoetis shares are owned by institutional investors. Comparatively, 66.7% of Johnson & Johnson shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 0.3% of Johnson & Johnson shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Zoetis and Johnson & Johnson's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.68 billion13.19$1.64 billion$3.8548.16
Johnson & Johnson$82.58 billion5.25$14.71 billion$8.0320.49

Johnson & Johnson has higher revenue and earnings than Zoetis. Johnson & Johnson is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and price targets for Zoetis and Johnson & Johnson, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis06702.54
Johnson & Johnson021002.83

Zoetis presently has a consensus price target of $184.25, indicating a potential downside of 0.64%. Johnson & Johnson has a consensus price target of $185.70, indicating a potential upside of 12.88%. Given Johnson & Johnson's stronger consensus rating and higher possible upside, analysts plainly believe Johnson & Johnson is more favorable than Zoetis.

Summary

Johnson & Johnson beats Zoetis on 10 of the 17 factors compared between the two stocks.

Pfizer (NYSE:PFE) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends and analyst recommendations.

Insider & Institutional Ownership

64.2% of Pfizer shares are held by institutional investors. Comparatively, 90.2% of Zoetis shares are held by institutional investors. 0.1% of Pfizer shares are held by company insiders. Comparatively, 0.2% of Zoetis shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Pfizer and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Pfizer22.09%24.55%9.61%
Zoetis25.30%55.11%14.70%

Dividends

Pfizer pays an annual dividend of $1.56 per share and has a dividend yield of 3.9%. Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Pfizer pays out 70.3% of its earnings in the form of a dividend. Zoetis pays out 26.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Pfizer has increased its dividend for 1 consecutive years and Zoetis has increased its dividend for 1 consecutive years.

Earnings and Valuation

This table compares Pfizer and Zoetis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pfizer$41.91 billion5.29$9.62 billion$2.2217.83
Zoetis$6.68 billion13.19$1.64 billion$3.8548.16

Pfizer has higher revenue and earnings than Zoetis. Pfizer is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Pfizer has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent recommendations for Pfizer and Zoetis, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pfizer011202.15
Zoetis06702.54

Pfizer currently has a consensus target price of $40.2857, indicating a potential upside of 1.76%. Zoetis has a consensus target price of $184.25, indicating a potential downside of 0.64%. Given Pfizer's higher possible upside, equities research analysts plainly believe Pfizer is more favorable than Zoetis.

Summary

Zoetis beats Pfizer on 11 of the 16 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and Eli Lilly and (NYSE:LLY) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Zoetis and Eli Lilly and, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis06702.54
Eli Lilly and021112.93

Zoetis currently has a consensus target price of $184.25, indicating a potential downside of 0.64%. Eli Lilly and has a consensus target price of $211.7143, indicating a potential downside of 5.11%. Given Zoetis' higher probable upside, analysts clearly believe Zoetis is more favorable than Eli Lilly and.

Profitability

This table compares Zoetis and Eli Lilly and's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.30%55.11%14.70%
Eli Lilly and23.91%132.28%16.36%

Institutional & Insider Ownership

90.2% of Zoetis shares are owned by institutional investors. Comparatively, 81.6% of Eli Lilly and shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 0.1% of Eli Lilly and shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Zoetis and Eli Lilly and's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.68 billion13.19$1.64 billion$3.8548.16
Eli Lilly and$24.54 billion8.72$6.19 billion$7.9328.13

Eli Lilly and has higher revenue and earnings than Zoetis. Eli Lilly and is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Zoetis has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Eli Lilly and has a beta of 0.24, suggesting that its stock price is 76% less volatile than the S&P 500.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Eli Lilly and pays an annual dividend of $3.40 per share and has a dividend yield of 1.5%. Zoetis pays out 26.0% of its earnings in the form of a dividend. Eli Lilly and pays out 42.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and Eli Lilly and has raised its dividend for 1 consecutive years.

Summary

Eli Lilly and beats Zoetis on 9 of the 17 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and AbbVie (NYSE:ABBV) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, valuation, analyst recommendations and dividends.

Analyst Recommendations

This is a breakdown of recent ratings for Zoetis and AbbVie, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis06702.54
AbbVie111102.77

Zoetis currently has a consensus target price of $184.25, indicating a potential downside of 0.64%. AbbVie has a consensus target price of $119.4615, indicating a potential upside of 3.29%. Given AbbVie's stronger consensus rating and higher probable upside, analysts clearly believe AbbVie is more favorable than Zoetis.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. AbbVie pays an annual dividend of $5.20 per share and has a dividend yield of 4.5%. Zoetis pays out 26.0% of its earnings in the form of a dividend. AbbVie pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and AbbVie has raised its dividend for 49 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Profitability

This table compares Zoetis and AbbVie's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.30%55.11%14.70%
AbbVie10.28%136.75%12.95%

Risk & Volatility

Zoetis has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Valuation & Earnings

This table compares Zoetis and AbbVie's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.68 billion13.19$1.64 billion$3.8548.16
AbbVie$45.80 billion4.46$4.62 billion$10.5610.95

AbbVie has higher revenue and earnings than Zoetis. AbbVie is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

90.2% of Zoetis shares are owned by institutional investors. Comparatively, 66.1% of AbbVie shares are owned by institutional investors. 0.2% of Zoetis shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

AbbVie beats Zoetis on 10 of the 17 factors compared between the two stocks.

Zoetis (NYSE:ZTS) and Merck & Co., Inc. (NYSE:MRK) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Zoetis and Merck & Co., Inc., as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Zoetis06702.54
Merck & Co., Inc.03902.75

Zoetis presently has a consensus price target of $184.25, indicating a potential downside of 0.64%. Merck & Co., Inc. has a consensus price target of $96.1111, indicating a potential upside of 27.38%. Given Merck & Co., Inc.'s stronger consensus rating and higher probable upside, analysts plainly believe Merck & Co., Inc. is more favorable than Zoetis.

Dividends

Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Merck & Co., Inc. pays an annual dividend of $2.60 per share and has a dividend yield of 3.4%. Zoetis pays out 26.0% of its earnings in the form of a dividend. Merck & Co., Inc. pays out 43.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Zoetis has raised its dividend for 1 consecutive years and Merck & Co., Inc. has raised its dividend for 1 consecutive years.

Profitability

This table compares Zoetis and Merck & Co., Inc.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Zoetis25.30%55.11%14.70%
Merck & Co., Inc.14.64%54.15%16.33%

Risk and Volatility

Zoetis has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Merck & Co., Inc. has a beta of 0.4, meaning that its share price is 60% less volatile than the S&P 500.

Valuation and Earnings

This table compares Zoetis and Merck & Co., Inc.'s top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zoetis$6.68 billion13.19$1.64 billion$3.8548.16
Merck & Co., Inc.$47.99 billion3.98$7.07 billion$5.9412.70

Merck & Co., Inc. has higher revenue and earnings than Zoetis. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

90.2% of Zoetis shares are held by institutional investors. Comparatively, 72.0% of Merck & Co., Inc. shares are held by institutional investors. 0.2% of Zoetis shares are held by insiders. Comparatively, 0.3% of Merck & Co., Inc. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Merck & Co., Inc. beats Zoetis on 9 of the 16 factors compared between the two stocks.

Bristol-Myers Squibb (NYSE:BMY) and Zoetis (NYSE:ZTS) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.

Dividends

Bristol-Myers Squibb pays an annual dividend of $1.96 per share and has a dividend yield of 2.9%. Zoetis pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Bristol-Myers Squibb pays out 30.4% of its earnings in the form of a dividend. Zoetis pays out 26.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Bristol-Myers Squibb has raised its dividend for 1 consecutive years and Zoetis has raised its dividend for 1 consecutive years.

Institutional & Insider Ownership

71.8% of Bristol-Myers Squibb shares are owned by institutional investors. Comparatively, 90.2% of Zoetis shares are owned by institutional investors. 0.1% of Bristol-Myers Squibb shares are owned by insiders. Comparatively, 0.2% of Zoetis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Bristol-Myers Squibb and Zoetis' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bristol-Myers Squibb$42.52 billion3.54$-9,015,000,000.00$6.4410.45
Zoetis$6.68 billion13.19$1.64 billion$3.8548.16

Zoetis has lower revenue, but higher earnings than Bristol-Myers Squibb. Bristol-Myers Squibb is trading at a lower price-to-earnings ratio than Zoetis, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Bristol-Myers Squibb and Zoetis, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Bristol-Myers Squibb031012.86
Zoetis06702.54

Bristol-Myers Squibb presently has a consensus price target of $72.8462, indicating a potential upside of 8.19%. Zoetis has a consensus price target of $184.25, indicating a potential downside of 0.64%. Given Bristol-Myers Squibb's stronger consensus rating and higher probable upside, analysts plainly believe Bristol-Myers Squibb is more favorable than Zoetis.

Profitability

This table compares Bristol-Myers Squibb and Zoetis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Bristol-Myers Squibb-14.53%33.76%12.19%
Zoetis25.30%55.11%14.70%

Volatility & Risk

Bristol-Myers Squibb has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Zoetis has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Summary

Zoetis beats Bristol-Myers Squibb on 10 of the 17 factors compared between the two stocks.

Ad Mining News Daily
Silver Glitters More Than Gold
Silver just hit a 7-year high making this junior silver stock an exciting one to watch

Zoetis Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Johnson & Johnson logo
JNJ
Johnson & Johnson
2.5$164.51+0.5%$435.49 billion$82.58 billion29.07
Pfizer logo
PFE
Pfizer
1.9$39.59+0.1%$221.84 billion$41.91 billion20.20Analyst Report
Analyst Revision
Eli Lilly and logo
LLY
Eli Lilly and
2.0$223.11+1.3%$214.91 billion$24.54 billion33.35Analyst Report
AbbVie logo
ABBV
AbbVie
2.4$115.66+0.2%$203.86 billion$45.80 billion40.87
Merck & Co., Inc. logo
MRK
Merck & Co., Inc.
2.4$75.45+0.0%$193.12 billion$47.99 billion27.34
Bristol-Myers Squibb logo
BMY
Bristol-Myers Squibb
1.9$67.33+0.1%$150.36 billion$42.52 billion-24.22
Royalty Pharma logo
RPRX
Royalty Pharma
1.9$44.02+1.4%$27.09 billion$2.12 billion27.51Insider Selling
Decrease in Short Interest
Horizon Therapeutics Public logo
HZNP
Horizon Therapeutics Public
2.1$91.73+0.9%$20.97 billion$2.20 billion79.08
Jazz Pharmaceuticals logo
JAZZ
Jazz Pharmaceuticals
2.0$183.87+1.4%$10.61 billion$2.36 billion20.16News Coverage
Perrigo logo
PRGO
Perrigo
2.0$47.59+0.3%$6.37 billion$5.06 billion-27.99
Nektar Therapeutics logo
NKTR
Nektar Therapeutics
1.7$17.76+0.5%$3.22 billion$152.91 million-7.43
Pacira BioSciences logo
PCRX
Pacira BioSciences
1.9$59.59+0.7%$2.64 billion$429.65 million17.95
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.9$21.83+1.1%$2.51 billion$353.87 million27.99News Coverage
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
2.1$31.81+0.5%$1.70 billion$520.40 million15.37
Endo International logo
ENDP
Endo International
1.7$5.44+3.3%$1.46 billion$2.90 billion13.60
Zogenix logo
ZGNX
Zogenix
1.7$17.50+4.7%$1.02 billion$13.64 million-4.07
Omeros logo
OMER
Omeros
1.6$14.90+4.3%$968.58 million$73.81 million-6.11
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.4$10.09+3.4%$489.46 million$46.92 million-5.26
Forest Road Acquisition logo
FRX
Forest Road Acquisition
0.7$10.03+2.3%$388.50 millionN/A0.00
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.6$3.55+2.3%$357.74 million$156.47 million14.20
Lannett logo
LCI
Lannett
2.1$4.74+4.9%$216.76 million$545.74 million-0.96
Assembly Biosciences logo
ASMB
Assembly Biosciences
1.6$4.16+2.2%$175.89 million$79.11 million-2.45
Cumberland Pharmaceuticals logo
CPIX
Cumberland Pharmaceuticals
0.9$3.02+2.0%$46.51 million$37.44 million-21.57
This page was last updated on 6/15/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.